This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Steatohepatitis is a serious liver disease that can lead to liver failure. It is caused by the accumulation of fat in the liver, and it is most commonly caused by obesity or over-eating. There are several different types of steatohepatitis, and each is associated with a different set of symptoms. The most common type of steatohepatitis is called non-alcoholic steatohepatitis (NASH), and it is caused by the accumulation of fat in the liver without the presence of alcohol. NASH is the most common cause of chronic liver disease, and it is estimated that about one-third of all people who develop liver disease have NASH. Other types of steatohepatitis include alcoholic steatohepatitis (ASH), which is caused by the accumulation of fat in the liver after drinking alcohol, and non-alcoholic steatohepatitis with cirrhosis (NASH-C), which is caused by the accumulation of fat in the liver after developing cirrhosis caused by another disease. In most cases, steatohepatitis is a progressive disease, and the more fat that accumulates in the liver, the more damage it can do. Symptoms of steatohepatitis can include abdominal pain, cirrhosis, and liver failure. There is no cure for steatohepatitis, but treatment focuses on managing the symptoms and preventing further damage. Treatment options include diet, exercise, and medication. Some people may also need surgery to remove the fat from the liver. The most important thing to remember about steatohepatitis is that it is a serious and potentially life-threatening disease.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States